AMPH reported meaningful declines in profitability and operating cash flow despite successful new product launches, with net income falling 38.5% year-over-year.
The company's core profitability metrics deteriorated significantly even as it expanded its commercial portfolio with three new FDA-approved products launched or pending launch. The combination of reduced earnings alongside higher R&D spending suggests either margin pressure on existing products or substantial launch costs that have yet to generate offsetting revenue benefits.
AMPH experienced a challenging financial year with net income declining 38.5% to $98.1M and operating income falling 31.7% to $140.4M, while operating cash flow dropped 26.8% to $156.1M. The company increased R&D spending by 16.1% to $85.8M, likely supporting its pipeline development efforts. Despite the earnings pressure, the balance sheet remained healthy with current assets growing 19.1% to $636.0M, cash increasing 12.2% to $170.2M, and stockholders' equity rising 10.7% to $445.5M, suggesting the company maintained financial flexibility during this transition period.
Net income declined 38.5% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Current assets grew 19.1% — improving short-term liquidity or inventory/receivables build.
R&D investment increased 16.1% — signals commitment to future product development, though near-term margin impact.
Inventory built 15.1% — monitor whether demand supports this build or if write-downs may follow.
Cash grew 12.2% — improving liquidity position supports investment and shareholder returns.
Buyback activity reduced 11.6% — capital being redeployed elsewhere or cash conservation underway.
Equity base grew 10.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →